Semin Neurol 2022; 42(02): 182-191
DOI: 10.1055/s-0042-1742582
Review Article

Neuropsychiatric Treatments for Epilepsy: Nonpharmacological Approaches

1   Division of Epilepsy and Comprehensive Epilepsy Center, Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida
2   Department of Neurology. Division of Epilepsy, Epilepsy Center of Excellence, Miami VA Medical Center, Miami, Florida
,
Andres M. Kanner
1   Division of Epilepsy and Comprehensive Epilepsy Center, Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida
› Institutsangaben

Abstract

Neuropsychiatric conditions are frequently found in patients with epilepsy (PWE). These entities can be as disabling as epilepsy resulting in a significant negative impact on the quality of life of this population if not addressed and treated appropriately. In this article, we provide an overview of non-pharmacological treatments currently available to these patients—and review their effect on mood and anxiety disorders as well as epilepsy. These treatment strategies will allow the practitioner to optimize clinical care during the initial evaluation, which begins with the recognition of the neuropsychiatric condition followed by the appropriate individualized psychotherapeutic approach and/or neuromodulation therapy. To plan a comprehensive treatment for PWE, practitioners must be familiar with these therapeutic tools. Additional clinical research is needed to further create a multidisciplinary team in the assessment and management of neuropsychiatric disorders in PWE.



Publikationsverlauf

Artikel online veröffentlicht:
25. Februar 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Mula M, Kanner AM, Jetté N, Sander JW. Psychiatric comorbidities in people with epilepsy. Neurol Clin Pract 2021; 11 (02) e112-e120
  • 2 Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48 (12) 2336-2344
  • 3 Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012; 72 (02) 184-191
  • 4 Chang YT, Chen PC, Tsai IJ. et al. Bidirectional relation between schizophrenia and epilepsy: a population-based retrospective cohort study. Epilepsia 2011; 52 (11) 2036-2042
  • 5 Jossephson CB, Lowerison M, Vallerand I. et al. Association of depression and treated depression with epilepsy and seizure outcomes: a multicohort analysis. JAMA Neurol 2017; May 1; 74 (05) 533-539
  • 6 Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75 (2-3): 192-196
  • 7 Petrovski S, Szoeke CEI, Jones NC. et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010; 75 (11) 1015-1021
  • 8 Nogueira MH, Yasuda CL, Coan AC, Kanner AM, Cendes F. Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia 2017; 58 (07) 1268-1276
  • 9 Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. Lancet Neurol 2012; 11 (12) 1093-1102
  • 10 Kanner AM, Mazarati A, Koepp M. Biomarkers of epileptogenesis: psychiatric comorbidities (?). Neurotherapeutics 2014; 11 (02) 358-372
  • 11 Taher TR, Salzberg M, Morris MJ, Rees S, O'Brien TJ. Chronic low-dose corticosterone supplementation enhances acquired epileptogenesis in the rat amygdala kindling model of TLE. Neuropsychopharmacology 2005; 30 (09) 1610-1616
  • 12 Kumar G, Couper A, O'Brien TJ. et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007; 32 (07) 834-842
  • 13 Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46
  • 14 Vezzani A, Conti M, De Luigi A. et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19 (12) 5054-5065
  • 15 Haut SR, Vouyiouklis M, Shinnar S. Stress and epilepsy: a patient perception survey. Epilepsy Behav 2003; 4 (05) 511-514
  • 16 Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol 2016; 12 (02) 106-116
  • 17 Finkelstein SA, Adams C, Tuttle M, Saxena A, Perez DL. Neuropsychiatric treatment approaches for functional neurological disorder: a how to guide. Semin Neurol 2022; 42 (02) 204-224
  • 18 Michaelis R, Tang V, Wagner JJ. et al. Psychological treatments for people with epilepsy. 2017; 2017 (10) CD012081
  • 19 Fargo JD, Schefft BK, Szaflarski JP. et al. Accuracy of self-reported neuropsychological functioning in individuals with epileptic or psychogenic nonepileptic seizures. Epilepsy Behav 2004; 5 (02) 143-150
  • 20 Michaelis R, Tang V, Wagner JL. et al. Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life. Epilepsia 2018; 59 (02) 315-332
  • 21 Dewhurst E, Novakova B, Reuber M. A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy. Epilepsy Behav 2015; 46: 234-241
  • 22 Miller L. Psychotherapy of epilepsy: seizure control and psychosocial adjustment. J Cogn Rehabil 1994; 31 (04) 735-743
  • 23 Gerber AJ, Kocsis JH, Milrod BL. et al. A quality-based review of randomized controlled trials of psychodynamic psychotherapy. Am J Psychiatry 2011; 168 (01) 19-28
  • 24 Summers RF, Barber JP. Psychodynamic Therapy: A Guide to Evidence-Based Practice. Guilford Press; 2010
  • 25 Binder JL. Key Competencies in Brief Dynamic Psychotherapy: Clinical Practice beyond the Manual. Guilford Press; 2004
  • 26 Tang V, Michaelis R, Kwan P. Psychobehavioral therapy for epilepsy. Epilepsy Behav 2014; 32: 147-155
  • 27 Gandy M, Sharpe L, Perry KNJE. Cognitive behavior therapy for depression in people with epilepsy: a systematic review. Epilepsia 2013; 54 (10) 1725-1734
  • 28 Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006; 26 (01) 17-31
  • 29 Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 2015; 163 (03) 191-204
  • 30 McLaughlin DP, McFarland K. A randomized trial of a group based cognitive behavior therapy program for older adults with epilepsy: the impact on seizure frequency, depression and psychosocial well-being. J Behav Med 2011; 34 (03) 201-207
  • 31 Elsas SM, Gregory WL, White G, Navarro G, Salinsky MC, Andrews DJ. Aura interruption: the Andrews/Reiter behavioral intervention may reduce seizures and improve quality of life - a pilot trial. Epilepsy Behav 2011; 22 (04) 765-772
  • 32 Michaelis R, Tang V, Goldstein LH. et al. Psychological treatments for adults and children with epilepsy: evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia 2018; 59 (07) 1282-1302
  • 33 Schmid-Schönbein C. Improvement of seizure control by psychological methods in patients with intractable epilepsies. Seizure 1998; 7 (04) 261-270
  • 34 Au A, Chan F, Li K, Leung P, Li P, Chan J. Cognitive-behavioral group treatment program for adults with epilepsy in Hong Kong. Epilepsy Behav 2003; 4 (04) 441-446
  • 35 Reiter J, Andrews D, Janis C. Taking Control of Your Epilepsy: A Workbook for Patients and Professionals. Basics Publishing Company; 1987
  • 36 Goldstein LH, McAlpine M, Deale A, Toone BK, Mellers JD. Cognitive behaviour therapy with adults with intractable epilepsy and psychiatric co-morbidity: preliminary observations on changes in psychological state and seizure frequency. Behav Res Ther 2003; 41 (04) 447-460
  • 37 Noble AJ, Reilly J, Temple J, Fisher PL. Cognitive-behavioural therapy does not meaningfully reduce depression in most people with epilepsy: a systematic review of clinically reliable improvement. J Neurol Neurosurg Psychiatry 2018; 89 (11) 1129-1137
  • 38 Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and depression: a systematic literature review. Epilepsy Behav 2013; 28 (01) 36-40
  • 39 Macrodimitris S, Wershler J, Hatfield M. et al. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. Epilepsy Behav 2011; 20 (01) 83-88
  • 40 Kabat-Zinn J. Mindfulness-based interventions in context: past, present, and future. Clin Psychol Sci Pract 2003; 10 (02) 144-156
  • 41 Baslet G, Tolchin B, Dworetzky BA. Altered responsiveness in psychogenic nonepileptic seizures and its implication to underlying psychopathology. Seizure 2017; 52: 162-168
  • 42 Lai S-T, Lim K-S, Low W-Y, Tang V. Positive psychological interventions for neurological disorders: a systematic review. Clin Neuropsychol 2019; 33 (03) 490-518
  • 43 Lai S-T, Lim K-S, Tang V, Low W-YJE. Mindfulness-based intervention to promote psychological wellbeing in people with epilepsy: a randomized controlled trial. Epilepsy Behav 2021; 118: 107916
  • 44 Wood K, Lawrence M, Jani B, Simpson R, Mercer SW. Mindfulness-based interventions in epilepsy: a systematic review. BMC Neurol Mar 20 2017; 17 (01) 52
  • 45 Sathyaprabha TN, Satishchandra P, Pradhan C. et al. Modulation of cardiac autonomic balance with adjuvant yoga therapy in patients with refractory epilepsy. Epilepsy Behav 2008; 12 (02) 245-252
  • 46 Rousseau A, Hermann B, Whitman S. Effects of progressive relaxation on epilepsy: analysis of a series of cases. Psychol Rep 1985; 57 (suppl 3 Pt 2): 1203-1212
  • 47 Panebianco M, Sridharan K, Ramaratnam S. Yoga for epilepsy. 2017; Oct 5; 10 (10) CD001524
  • 48 Brown NW. Psychoeducational Groups: Process and Practice. Routledge; 2018
  • 49 Thompson NJ, Walker ER, Obolensky N. et al. Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav 2010; 19 (03) 247-254
  • 50 Ciechanowski P, Chaytor N, Miller J. et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 2010; 19 (03) 225-231
  • 51 Helgeson DC, Mittan R, Tan SY, Chayasirisobhon S. Sepulveda epilepsy education: the efficacy of a psychoeducational treatment program in treating medical and psychosocial aspects of epilepsy. Epilepsia 1990; 31 (01) 75-82
  • 52 Fraser RT, Johnson EK, Lashley S. et al. PACES in epilepsy: results of a self-management randomized controlled trial. Epilepsia 2015; 56 (08) 1264-1274
  • 53 DiIorio C, Bamps Y, Walker ER, Escoffery C. Results of a research study evaluating WebEase, an online epilepsy self-management program. Epilepsy Behav 2011; 22 (03) 469-474
  • 54 Sajatovic M, Tatsuoka C, Welter E. et al. Targeted self-management of epilepsy and mental illness for individuals with epilepsy and psychiatric comorbidity. Epilepsy Behav 2016; 64 (Pt A): 152-159
  • 55 Caller TA, Ferguson RJ, Roth RM. et al. A cognitive behavioral intervention (HOBSCOTCH) improves quality of life and attention in epilepsy. Epilepsy Behav 2016; 57 (Pt A): 111-117
  • 56 Sajatovic M, Colon-Zimmermann K, Kahriman M. et al. One-year follow-up of a remotely delivered epilepsy self-management program in high-risk people with epilepsy. Epilepsy Behav 2019; 96: 237-243
  • 57 Jantzen S, Müller-Godeffroy E, Hallfahrt-Krisl T. et al. FLIP&FLAP-a training programme for children and adolescents with epilepsy, and their parents. Seizure 2009; 18 (07) 478-486
  • 58 Rau J, May TW, Pfäfflin M, Heubrock D, Petermann F. Education of children with epilepsy and their parents by the modular education program epilepsy for families (FAMOSES)—results of an evaluation study. Rehabilitation (Stuttg) 2006; 45 (01) 27-39
  • 59 May TW, Pfäfflin M. Modular Service Package Epilepsy. The efficacy of an educational treatment program for patients with epilepsy (MOSES): results of a controlled, randomized study. Epilepsia 2002; 43 (05) 539-549
  • 60 Ridsdale L, Kralj-Hans I, Noble A. et al. Self-management education for epilepsy: an RCT protocol. J Neurol Neurosurg Psychiatry 2014; 85 (10) A20-A21
  • 61 Etemadifar S, Heidari M, Jivad N, Masoudi R. Effects of family-centered empowerment intervention on stress, anxiety, and depression among family caregivers of patients with epilepsy. Epilepsy Behav 2018; 88: 106-112
  • 62 Hosseini N, Mokhtari S, Momeni E, Vossoughi M, Barekatian M. Effect of motivational interviewing on quality of life in patients with epilepsy. Epilepsy Behav 2016; 55: 70-74
  • 63 Mark C, Eldaief MC, Camprodon JA. Neuromodulation for the neurological patient: scientific principles and applications. Semin Neurol 2022
  • 64 Pakpour AH, Gholami M, Esmaeili R. et al. A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence. Epilepsy Behav 2015; 52 (Pt A): 133-142
  • 65 Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure 2020; 83: 104-123
  • 66 Ryvlin P, Gilliam FG, Nguyen DK. et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia 2014; 55 (06) 893-900
  • 67 Morris III GL, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999; 53 (08) 1731-1735
  • 68 Rush AJ, Marangell LB, Sackeim HA. et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58 (05) 347-354
  • 69 Rush AJ, Sackeim HA, Marangell LB. et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005; 58 (05) 355-363
  • 70 Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006; 318 (02) 890-898
  • 71 Raedt R, Clinckers R, Mollet L. et al. Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure model. J Neurochem 2011; 117 (03) 461-469
  • 72 Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998; 39 (07) 709-714
  • 73 Miyamoto O, Pang J, Sumitani K, Negi T, Hayashida Y, Itano T. Mechanisms of the anti-ischemic effect of vagus nerve stimulation in the gerbil hippocampus. Neuroreport 2003; 14 (15) 1971-1974
  • 74 Meneses G, Bautista M, Florentino A. et al. Electric stimulation of the vagus nerve reduced mouse neuroinflammation induced by lipopolysaccharide. J Inflamm (Lond) 2016; 13: 33
  • 75 McLachlan RS, Sadler M, Pillay N. et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor?. Eur Neurol 2003; 50 (01) 16-19
  • 76 Kawai K, Tanaka T, Baba H. et al. Outcome of vagus nerve stimulation for drug-resistant epilepsy: the first three years of a prospective Japanese registry. Epileptic Disord 2017; 19 (03) 327-338
  • 77 Englot DJ, Hassnain KH, Rolston JD, Harward SC, Sinha SR, Haglund MM. Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data. Epilepsy Behav 2017; 66: 4-9
  • 78 Ryvlin P, So EL, Gordon CM. et al. Long-term surveillance of SUDEP in drug-resistant epilepsy patients treated with VNS therapy. Epilepsia 2018; 59 (03) 562-572
  • 79 Harden CL, Pulver MC, Ravdin LD, Nikolov B, Halper JP, Labar DR. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000; 1 (02) 93-99
  • 80 Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000; 42 (2-3): 203-210
  • 81 Spindler P, Bohlmann K, Straub HB, Vajkoczy P, Schneider UC. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure 2019; 69: 77-79
  • 82 Klinkenberg S, Majoie HJM, van der Heijden MMAA, Rijkers K, Leenen L, Aldenkamp AP. Vagus nerve stimulation has a positive effect on mood in patients with refractory epilepsy. Clin Neurol Neurosurg 2012; 114 (04) 336-340
  • 83 Kim JS, Kim DY, Jo HJ. et al. Effect of long-term treatment with vagus nerve stimulation on mood and quality of life in Korean patients with drug-resistant epilepsy. J Clin Neurol 2021; 17 (03) 385-392
  • 84 Nahas Z, Marangell LB, Husain MM. et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005; 66 (09) 1097-1104
  • 85 Bajbouj M, Merkl A, Schlaepfer TE. et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol 2010; 30 (03) 273-281
  • 86 Aaronson ST, Sears P, Ruvuna F. et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry 2017; 174 (07) 640-648
  • 87 Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry 2018; 23 (05) 1094-1112
  • 88 Zhou C, Zhang H, Qin Y. et al. A systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2018; 82: 224-232
  • 89 Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. JAMA Psychiatry 2018; 75 (07) 713-722
  • 90 Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul 2016; 9 (03) 336-346
  • 91 Zeiler FA, Matuszczak M, Teitelbaum J, Gillman LM, Kazina CJ. Electroconvulsive therapy for refractory status epilepticus: a systematic review. Seizure 2016; 35: 23-32
  • 92 Lunde ME, Lee EK, Rasmussen KG. Electroconvulsive therapy in patients with epilepsy. Epilepsy Behav 2006; 9 (02) 355-359
  • 93 Spacek A, Neiger FX, Krenn CG, Hoerauf K, Kress HG. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 1999; 90 (01) 109-112
  • 94 Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT 2014; 30 (01) 5-9
  • 95 Rossi S, Antal A, Bestmann S. et al; basis of this article began with a Consensus Statement from the IFCN Workshop on “Present, Future of TMS: Safety, Ethical Guidelines”, Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clin Neurophysiol 2021; 132 (01) 269-306
  • 96 Chen R, Spencer DC, Weston J, Nolan SJ. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database Syst Rev 2016; 11 (08) CD011025 DOI: 10.1002/14651858.CD011025.pub2. . Update in: Cochrane Database Syst Rev. 2021 Apr 15;4:CD011025. PMID: 27513825
  • 97 Pereira LS, Müller VT, da Mota Gomes M, Rotenberg A, Fregni F. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: a systematic review. Epilepsy Behav 2016; 57 (Pt A): 167-176